CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease

Abstract

AbstractBackgroundAlzheimer’s disease (AD) is the most common form of neurodegenerative disease and most anti‐AD drugs have failed in clinical trials, hence it is urgent to find effective potential drugs against AD. DL‐3‐n‐Butylphthalide (NBP) is a compound extracted from celery seed and is a multiple‐target drug, and we have demonstrated NBP was effective for improving cognitive and global functioning in patients with subcortical vascular cognitive impairment without dementia and exhibited good safety. Even though there are several studies that have demonstrated the neuroprotective effects of NBP on cognitive impairment, and the mechanisms of NBP remains relatively unexplored.MethodCell viabilities was observed by MTT. Apoptosis and the level of intracellular Ca2+ were examined by flow cytometry. The activation of CaMKIIα signaling was detected by western blotting and immunofluorescence.ResultIn this study, we found that NBP could alleviated the increase of intracellular Ca2+ and reverse down‐regulation of Ca2+/calmodulin‐dependent protein kinase alpha (CaMKIIα) signaling, and rescue neuronal apoptosis in SH‐SY5Y cells treated by Aβ oligomers. Further, we found that these neuroprotection of NBP on neuronal damage and CaMKIIα signaling were abolished when CaMKIIα expression was knock‐downed or its activity was inhibited.ConclusionThus, our findings suggested that CaMKIIα signaling was required for the neuroprotective effects of NBP in AD, and provide an improved basis for elucidation of the mechanism and treatment of NBP in AD.